GC-506 is under clinical development by Gracell Biotechnologies and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GC-506’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GC-506 overview
GC-506 is under development for the treatment of claudin 18.2 positive solid tumors including gastric cancer, gastroesophageal junction adenocarcinoma. The therapies comprise T cells genetically modified to express chimeric antigen receptor (CAR) targeting cells expressing claudin 18.2 (CLDN18.2). The drug candidate is being developed based on SMART CARTTM platform. The therapeutic candidate is administered through parenteral route.
Gracell Biotechnologies overview
Gracell Biotechnologies, a subsidiary of AstraZeneca Plc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative cell therapies aimed at addressing unmet medical needs in the treatment of cancer and autoimmune diseases. The company is headquartered in Shanghai, China.
For a complete picture of GC-506’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
